Helsinki, September 2025 – MVision AI, a pioneer in AI solutions for radiotherapy, today announced that Mahmudul Hasan, the company’s Founder and Executive Director, is returning to the role of Chief Executive Officer (CEO).
Hasan established MVision AI in 2017 and oversaw the company’s earliest successes. As part of a dedicated team, he recognized early on the pivotal role artificial intelligence would play in radiotherapy. Guided by this vision, MVision AI now operates in 24 countries and processes more than 200,000 scans globally each year.
Building on recent significant product momentum—including the launch of Workspace+ and FDA 510(k) clearance for Dose+—the MVision AI Board of Directors has reaffirmed its support for Hasan as CEO. Drawing on his founding experience and deep familiarity with MVision’s customers and products, Hasan returns to lead the company’s next phase with focused, hands-on leadership and continuity across teams.
As an early investor, board member, and now Chair of the Board, I’m thrilled to welcome Mahmudul back as CEO. In 2017 he understood well before most that AI would be instrumental to radiotherapy. Mahmudul and his team are charting the path toward a future where same-day radiotherapy becomes a reality,” said Pontus Stråhlman, Chairman of the Board of MVision AI.
Hasan’s return comes with the full support of the MVision AI team. With long-standing customer partnerships, and the accelerated pace of AI in radiotherapy, MVision is ready to further contribute to the progress in access and quality of care.
I’m happy to see Mahmud return and take the helm,” said Saad Ullah Akram, CTO and Co-Founder of MVision AI. “His product instincts and customer focus have been central to MVision’s progress; I’m confident he’ll lead us into the next phase of growth and innovation.
Near-term priorities include scaling deployments of Workspace+ and Dose+, and deepening clinical collaborations to support consistent, high-quality workflows. MVision will also continue investing in product quality, reliability and regulatory readiness as it enters new geographies.
I’m grateful to the Board for the opportunity to advance the founding vision I set in 2017 and to lead MVision again as CEO,” said Mahmudul Hasan. “Our mission then—and now—is to expand access to high-quality radiotherapy for every cancer patient. With a highly skilled, motivated team and the support of our stakeholders and clinical partners, we will keep advancing AI-enabled solutions that help ensure consistent, high-quality, same-day care for every patient.
About MVision AI
MVision AI develops software for standardized, efficient radiotherapy workflows. The portfolio centers on GBS™, MVision’s platform that includes Contour+, Guide, and Verify to support contouring, planning guidance, and contour evaluation. MVision also offers Dose+, an FDA 510(k)-cleared solution designed to support dose evaluation and quality across clinical settings.
For more information, visit www.mvision.ai or contact info@mvision.ai.